Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(443)
•••
Post by saintpeteron Mar 09, 2021 6:27pm
128 Views
Post# 32756050

todays trades

todays trades
House Positions for C:VXL from 20210309 to 20210309
House Bought $Val Ave Sold $Val Ave Net $Net
33 Canaccord 247,245 30,145 0.122 56,015 7,202 0.129 191,230 -22,943
2 RBC 354,949 45,511 0.128 246,385 31,923 0.13 108,564 -13,588
1 Anonymous 166,050 20,167 0.121 75,000 9,382 0.125 91,050 -10,785
19 Desjardins 95,100 11,612 0.122 16,300 2,037 0.125 78,800 -9,575
80 National Bank 165,456 20,412 0.123 130,913 16,610 0.127 34,543 -3,802
9 BMO Nesbitt 72,500 9,085 0.125 51,000 6,565 0.129 21,500 -2,520
53 Morgan Stanley 11,200 1,431 0.128 1,500 182 0.121 9,700 -1,249
68 Leede 14,835 1,861 0.125 9,882 1,271 0.129 4,953 -590
89 Raymond James 2,640 343 0.13 340 42 0.124 2,300 -301
212 Virtu 340 42 0.124 534 69 0.129 -194 27
14 ITG 1,300 166 0.128 3,499 437 0.125 -2,199 271
124 Questrade 0   4,745 610 0.129 -4,745 610
59 PI 0   30,000 3,707 0.124 -30,000 3,707
7 TD Sec 93,700 11,775 0.126 190,587 23,955 0.126 -96,887 12,180
79 CIBC 807,800 102,257 0.127 993,925 123,345 0.124 -186,125 21,088
85 Scotia 88,010 11,258 0.128 310,500 38,725 0.125 -222,490 27,467
TOTAL 2,121,125 266,065 0.125 2,121,125 266,062 0.125 0 -3

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities